Among the probes that were significantly regulated by two independent shRNAs targeting Fra-1 (P < 1×10−6) in both cell lines, we selected those showing a prognostic value in a cohort of 509 breast cancer patients. This evidence concerns the gene FOSL1 and breast carcinoma.